IP Library Granted Patent US 11,627,898
Granted Patent B2
US 11,627,898 · App. 16/175,157 · Granted Apr 18, 2023

Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same

Inventors: Marc B. Taub (Mountain View, CA); Jai Karan (Hyderabad, IN); Annie C. Tan (Redwood City, CA); Timothy C. Dunn (San Francisco, CA); Joel M. Goldsmith (Oakland, CA); Christine M. Neuhaus (San Jose, CA); Stephen A. Rossi (Clayton, CA); Sujit R. Jangam (Castro Valley, CA)
Assignee: ABBOTT DIABETES CARE INC.
A61B5/1473A61B5/14532G01N33/48792A61B5/0004A61B5/6833A61B5/6847A61B5/744A61B5/7435A61B2560/0209A61B2560/0252
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,627,898
App. No.
16/175,157
Granted
Apr 18, 2023
Kind
B2
Abstract

Analyte monitoring systems, devices, and methods associated with analyte monitoring devices, and devices incorporating the same are provided. Various graphical user interfaces (GUI) and navigation flows are provided for performing various features, activities, functions, etc., associated with the analyte monitoring device or system. Intuitive navigation is provided to enhance the interpretation of analyte measurements.

Claims (40)

1. A method of operating an electronic device in an analyte monitoring system, comprising:

displaying an insulin dose calculation screen;

exiting the insulin dose calculation screen before logging a calculated dose that is based on a result of a first analyte measurement;

permitting logging of the calculated dose for a predetermined period of time after the first analyte measurement; and

preventing logging of the calculated dose after the predetermined period of time after the first analyte measurement.

2. The method of claim 1 , wherein the screen comprises the calculated dose.

3. The method of claim 1 , wherein the insulin dose calculation screen enables logging of the calculated dose.

4. The method of claim 1 , wherein the insulin dose calculation screen enables adjusting the calculated dose.

5. The method of claim 1 , wherein the insulin dose calculation screen is exited by powering the electronic device off.

6. The method of claim 5 , further comprising:

powering the electronic device back on after the electronic device was powered off; and

displaying the insulin dose calculation screen if powering the electronic device back on occurs before lapse of the predetermined period of time.

7. The method of claim 6 , further comprising:

saving the insulin dose calculation screen prior to powering off the electronic device.

8. The method of claim 5 , further comprising:

powering the electronic device back on after the electronic device was powered off; and

displaying a screen that prompts for a second analyte measurement if powering the electronic device back on occurs after lapse of the predetermined period of time.

9. The method of claim 1 , further comprising:

receiving an indication to log the calculated dose to a logbook; and

associating the calculated dose with the first analyte measurement and with a time the first analyte measurement was performed.

10. The method of claim 9 , further comprising:

starting a countdown for an estimated amount of insulin remaining in-body at a time of logging the calculated dose.

11. An electronic device, comprising:

a display; and

processor circuitry operably coupled with the display and configured to:

cause display of an insulin dose calculation screen on the display;

permit, after the insulin dose calculation screen is exited and before a calculated dose is logged, a logging of the calculated dose if a predetermined period of time after a first analyte measurement has not lapsed, wherein the calculated dose is based on a result of the first analyte measurement; and

prevent the logging of the calculated dose after the predetermined period of time after the first analyte measurement has lapsed.

12. The electronic device of claim 11 , wherein the insulin dose calculation screen comprises the calculated dose.

13. The electronic device of claim 11 , wherein the insulin dose calculation screen enables logging of the calculated dose.

14. The electronic device of claim 11 , wherein the insulin dose calculation screen enables adjusting the calculated dose.

15. The electronic device of claim 11 , wherein the processor circuitry is configured to cause display of the insulin dose calculation screen if the analyte monitoring device is powered off and back on before lapse of the predetermined period of time.

16. The electronic device of claim 11 , wherein the processor circuitry is configured to save the insulin dose calculation screen if the analyte monitoring device is powered off while the insulin dose calculation screen is displayed.

17. The electronic device of claim 11 , wherein the processor circuitry is configured to display a screen that prompts for a second analyte measurement if the analyte monitoring device is powered off and back on after lapse of the predetermined period of time.

18. The electronic device of claim 11 , wherein the processor circuitry is configured to associate the calculated dose with the first analyte measurement and with a time the first analyte measurement was performed.

19. The electronic device of claim 18 , wherein the processor circuitry is configured to start a countdown for an estimated amount of insulin remaining in-body at a time of logging the calculated dose.

20. The electronic device of claim 11 , further comprising a memory operably coupled with the processor, the memory comprising a plurality of instructions that, when executed, cause the processor to:

display the insulin dose calculation screen;

permit, after the insulin dose calculation screen is exited and before the calculated dose is logged, the logging of the calculated dose if the predetermined period of time after the first analyte measurement has not lapsed; and

prevent the logging of the calculated dose after the predetermined period of time after the first analyte measurement has lapsed.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2020
From: TAUB, MARC B.; KARAN, JAI; TAN, ANNIE C.; DUNN, TIMOTHY C.; GOLDSMITH, JOEL M.; NEUHAUS, CHRISTINE M.; ROSSI, STEPHEN A.; JANGAM, SUJIT R.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 054074/0113 →
Continuity (7)
Continuation 14214430 · Mar 14, 2014
Continuation In Part 13407617 · Feb 28, 2012
Provisional Application 61801518 · Mar 15, 2013
Provisional Application 61492266 · Jun 1, 2011
Provisional Application 61489098 · May 23, 2011
Provisional Application 61447645 · Feb 28, 2011
Related Publication 20190183393A1 · Jun 20, 2019